Alkem Labs: US FDA inspection and subsidiary acquisition updates

Alkem Laboratories has announced the completion of a US FDA Bioresearch Monitoring (BIMO) inspection at its Bioequivalence Center in Taloja, Maharashtra, conducted between March 10th and March 13th, 2025. The company stated that no Form 483 was issued at the inspection's conclusion. Simultaneously, Alkem reported progress on its subsidiary Alkem Medtech Private Limited's acquisition of Bombay Ortho Industries Private Limited. A Share Purchase and Share Subscription Agreement was executed on March 15th, 2025. This acquisition, initially announced on February 7th, 2025, involves Alkem Medtech acquiring 100% stake in Bombay Ortho. The company affirmed that the disclosure regarding the acquisition is available on Alkem's website, compliant with Regulation 30(8) of the SEBI LODR Regulations.